Publish Date: 
Tuesday, November 26, 2019 - 13:45

New ceo for the translationa research institute

Professor Scott Bell will be the new CEO for the Translational Research Institute (TRI), taking over from Professor Carolyn Mountford in February 2020. He is currently Executive Director – Research, Metro North Hospital and Health Service.
 
“Professor Bell brings to TRI a proven ability, and the necessary experience, to provide the intellectual and strategic leadership needed to foster collaboration for innovation in the health sector,” said Emeritus Professor David Siddle, Chair of the Translational Research Institute Board.
 
“He has a long history of supporting multi-disciplinary research. Professor Bell has been the Principal Investigator on numerous pivotal clinical trials in cystic fibrosis. He is also a global Principal Investigator on a novel approach to combination therapies.”
 
Professor Bell is a Senior Physician of the Adult Cystic Fibrosis Centre at the Prince Charles Hospital where he has worked since 1996. The Centre has more than 300 patients. Cystic fibrosis (CF) is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys and intestine. Professor Bell has also led the Lung Bacteria Laboratory at QIMR Berghofer Medical Research Institute since 2014.
 
Professor Bell recently led strategy development at Metro North Health, where he undertook extensive engagement with the health service, primary care and academic organisations. This engagement identified knowledge translation as vital to support the implementation of evidence into practice. It also identified the importance of educating the next generation of clinicians and clinician researchers. 
 
“I am excited to be offered the opportunity to oversee the work already underway and work with the team in developing initiatives that will have the greatest impact,” said Professor Bell.
 
“I am looking forward to working with the leaders of TRI’s shareholder institutes to identify and promote translational research from bench to bedside and from bedside to the bench.”
 
Professor Bell has over 230 peer-reviewed publications and has received grant support in excess of $20 million over the last 10 years. His research interests include Cystic Fibrosis Microbiology and acquisition pathways from human infection. He is currently a Board Member for the European Cystic Fibrosis Society and the Brisbane Diamantina Health Partners. 

Professor Bell is part of a new $15 million cystic fibrosis research program that was recently launched.